To identify a means by which to disrupt such an alternative ROS defense system and thereby to enhance the efficacy of xCT-targeted therapy for HNSCC, we designed a drug screen to identify agents that sensitize sulfasalazine-resistant cancer cells to the xCT inhibitor. This evidence concerns the gene SLC7A11 and cancer.